Atea Pharmaceuticals (AVIR) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.40

Estimate

-$0.50

Surprise

+20.8%

Score today

4.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Atea Pharmaceuticals (AVIR) reported a narrower loss than forecast — adjusted EPS of -$0.40 against the -$0.50 estimate (a 20.8% beat on a still-unprofitable quarter).

• CORRECTION: Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.42) Estimate — benzinga, 2026-11-09
• Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results — fiscal.ai, 2026-11-09
• Atea Pharmaceuticals Q3 2026 Earnings Call Transcript — benzinga, 2026-11-09

TrendMatrix currently rates AVIR Hold at 4.7/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +20.8% surprise compares with a -7.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$4.24

Price target

$7.22

Stop

$3.94

Upside to target

+70.3%

Reward-to-risk

6.3:1

Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$353.7M

P/E (fwd)

-3.0

52-week range

$2.87–$6.45

Off 52-week high

34.3%

RSI (14)

55

Volume vs avg

0.16×

Score today

4.7/10